Parexel Unveils Combined Regulatory & Access Consulting Organization to Help Customers Optimize Delivery of New Therapies to Patients
Integration of world-class Regulatory and Market Access teams will help companies address Clinical, Regulatory and Market Access strategies in parallel to achieve faster, smarter and patient-led development strategy
BOSTON and DURHAM, N.C., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today unveiled its fully-integrated Regulatory & Access consulting organization designed to optimize clinical development from the earliest stages. Parexel’s newly formed Regulatory & Access team encompasses more than 1,000 on-staff consultants worldwide, including ~100 former regulators and HTA assessors, with extensive expertise and familiarity with the regulations, guidances and stakeholders that companies must navigate successfully to ensure new therapies reach the patients who need them.
“Today, achieving market authorization from a regulatory agency is only the first hurdle to a new therapy reaching the market,” said Paul Bridges, Senior Vice President, Regulatory & Access. “By more holistically considering the diverse requirements of regulators, payers and patients and aligning these insights with clinical development, companies can optimize their plans to drive smarter, more efficient and patient-focused strategies, leading to faster development and improved patient access to new medicines.”
Parexel’s Regulatory & Access consulting organization includes former regulators from global agencies including the U.S. FDA, U.K.’s MHRA and NMPA in China, therapeutic experts with deep technical expertise, market access specialists with proven health technology assessment (HTA) success and medical communication experts to position evidence for greater stakeholder engagement. The alignment of these capabilities is designed to ultimately save time and resources across the drug development lifecycle.
“We understand the goal of every drug development program is to deliver results for a patient in need,” added Peyton Howell, Executive Vice President and Chief Commercial & Strategy Officer. “Our Regulatory & Access organization was designed with the patient in mind, helping companies advance through regulatory and market access hurdles without unnecessary delay in order to reduce the time that a patient must wait for an innovative new therapy.”
For more information about Parexel Regulatory & Access, please visit our website.
About Parexel
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.
Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.
Parexel Contact
Media:
Wendy Ryan
wendy.ryan@parexel.com
(781) 434-5104
